Article
Microbiology
Maria Bousali, Timokratis Karamitros
Summary: This study investigated the preferential integration of hepatitis B virus (HBV) into specific genes and evaluated their contribution to hepatocellular carcinoma (HCC) development. The results suggested that 15 genes are frequently affected by HBV integrations and significantly associated with HBV-HCC.
Review
Oncology
Sheng-Han Wang, Shiou-Hwei Yeh, Pei-Jer Chen
Summary: HBV infection is a major risk factor for HCC globally, with chronic hepatitis B generating an inflammatory microenvironment that leads to genetic mutations in hepatocytes predisposing them to cancer. Male dominance in HBV-related HCC highlights the interplay between sex hormones and viral factors influencing carcinogenesis.
Article
Cell Biology
Selena Y. Lin, Adam Zhang, Jessica Lian, Jeremy Wang, Ting-Tsung Chang, Yih-Jyh Lin, Wei Song, Ying-Hsiu Su
Summary: The study identified 396 recurrently targeted genes (RTGs) in HBV-associated HCC, with 23 of them associated with carcinogenesis. Among the top three RTGs, TERT, MLL4/KMT2B, and PLEKHG4B were identified as most frequently targeted. Comprehensive analysis of these genes provides insights for potential drug development and disease management in HCC.
Article
Virology
Pranav P. Mathkar, Xun Chen, Arvis Sulovari, Dawei Li
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality, with about half of cases associated with hepatitis B virus (HBV) infections. Accurate identification of HBV integration sites is crucial for understanding the landscape of HCC genome. Through pathway enrichment analysis, it was found that HBV integrations were linked to various metabolism pathways. The VIcaller method showed potential in identifying novel clonal integrations in cancer-related genes.
Article
Immunology
Ruonan Sun, Jiawei Li, Xianyi Lin, Yidong Yang, Bing Liu, Tianbi Lan, Shuang Xiao, Anyi Deng, Zhinan Yin, Yan Xu, Zheng Xiang, Bin Wu
Summary: This study aimed to explore the changes in peripheral immunity in patients with HBV-related hepatocellular carcinoma (HBV-HCC). The results showed that circulating lymphocytes in HBV-HCC patients exhibited features of immune exhaustion, especially in patients with persistent viral replication and in those with intermediate and advanced HBV-HCC. The combination of CD3(+) T cells and CD8(+)HLADR(+)CD38(+) T cells may serve as a potential diagnostic indicator for HBV-HCC.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Fenglin Zhao, Xiaoyu Xie, Xu Tan, Hongli Yu, Miaomiao Tian, Huanran Lv, Chengyong Qin, Jianni Qi, Qiang Zhu
Summary: Approximately 250 million people worldwide suffer from chronic Hepatitis B virus infection, leading to significant public health challenges. Despite available vaccines and antiviral drugs, curing chronic hepatitis B remains a distant goal. HBV-encoded proteins, including surface antigen, core antigen, envelope antigen, HBx, and polymerase, play crucial roles in viral persistence and liver pathogenesis, offering potential avenues for new CHB therapies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Microbiology
Renxiang Xia, Jing Peng, Jian He, Ping Jiang, Chunyan Yuan, Xiaoli Liu, Yunqing Yao
Summary: This study investigated the clinical and virological characteristics of individuals in China with chronic occult hepatitis B virus infection (HBV) and their correlation with hepatocellular carcinoma (HCC). Findings revealed that there are at least 21 million individuals with occult HBV infection in China. The presence of HBcAb(+) indicated not only chronic HBV infection, but also a dangerous marker for surface antigen-negative patients. Regular check-ups every six months or one year are recommended for early detection of HCC in occult infection patients.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Immunology
Ya Fu, Fengling Fang, Hongyan Guo, Xialin Xiao, Yuhai Hu, Yongbin Zeng, Tianbin Chen, Songhang Wu, Ni Lin, Jinlan Huang, Ling Jiang, Qishui Ou, Can Liu
Summary: This study investigates the evolutionary characteristics of HBV X gene in the hepatocellular carcinoma microenvironment, and finds lower heterogeneity in tumor tissues and a location bias in X gene mutations. Additionally, the study reveals that HBx harboring mutation T81P/S101P/L123S promotes cell proliferation and increases genomic instability.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Oncology
Rui Wang, Zhijian Xu, Jiaping Tian, Qian Liu, Jingwen Dong, Lijuan Guo, Boning Hai, Xia Liu, Hangping Yao, Zhi Chen, Junjie Xu, Lijun Zhu, Haiyi Chen, Tingjun Hou, Weiliang Zhu, Jimin Shao
Summary: Pterostilbene is identified as a potent RR inhibitor targeting RRM2, which can effectively inhibit both HCC proliferation and HBV replication, showing potential for the treatment of HCC and HBV-related HCC.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Guangyuan Song, Xingxin Zhu, Zefeng Xuan, Long Zhao, Haijiang Dong, Jian Chen, Zequn Li, Wenfeng Song, Cheng Jin, Mengqiao Zhou, Haiyang Xie, Shusen Zheng, Penghong Song
Summary: In this study, we identified that GNA14 is downregulated in HCC and negatively correlated with HBV infection, vascular invasion, and prognosis. HBx regulates GNA14 through DNA methylation, affecting the Notch1 and JMJD6 pathways to inhibit tumor proliferation and metastasis. GNA14 shows potential as a biomarker and therapeutic target in HCC.
Article
Oncology
Yu-Chong Peng, Jing-Xuan Xu, Chuan-Fa Zeng, Xin-Hua Zhao, Xue-Mei You, Ping-Ping Xu, Le-Qun Li, Lu-Nan Qi
Summary: This study investigated the difference in gut microbiota in patients with operable HBV-HCC at different ages and explored the features and functions associated with different age groups. The findings are of significance in the development of novel treatment approaches for HCC at different ages.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Lung-Yi Mak, Ka-Shing Cheung, Rex Wan-Hin Hui, Danny Ka-Ho Wong, James Fung, Man-Fung Yuen, Wai-Kay Seto
Summary: This prospective study found that enhanced liver fibrosis (ELF) in chronic hepatitis B patients before spontaneous HBsAg seroclearance was associated with hepatocellular carcinoma (HCC). Furthermore, a 97% reduction in ELF was found to significantly decrease the risk of HCC development in patients aged 50 or above after spontaneous seroclearance.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Oncology
Guosheng Yuan, Rong Li, Qi Li, Xiaoyun Hu, Jian Ruan, Wenzhe Fan, Junjie Wang, Wei Huang, Mengya Zang, Jinzhang Chen
Summary: The study explored the effects of HBV load and antiviral therapy on anti-PD-1+ antiangiogenic therapy for HCC patients. Baseline HBV loads did not affect tumor responses, and continuous effective antiviral treatment can prevent HBV reactivation.
ANNALS OF TRANSLATIONAL MEDICINE
(2021)
Review
Biotechnology & Applied Microbiology
Yuan Zhang, Xiaorong Chen, Yajuan Cao, Zongguo Yang
Summary: APOBEC3 (A3) cytidine deaminases play important roles in inhibiting HBV infection, but their deaminated deoxycytidine activity can also cause cellular genetic mutations, affecting genomic stability and cancer development.
Review
Virology
Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxi
Summary: Hepatitis B virus (HBV) infection is associated with the risk of developing hepatocellular carcinoma (HCC), with or without liver cirrhosis, through various mechanisms. The molecular profile of HBV-HCC is constantly being studied, and it is the result of altered molecular pathways, changes in the microenvironment, and DNA damage. Proper management of HBV-related liver disease is crucial for prevention and treatment of HCC.